Wang YY - Search Results

1

Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.

Wang YY, Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN, Ning C, Zhang JW, Zhu CP, Zhang LH, Yang XB, Zhao HT. Wang YY, et al. Among authors: wang yc. World J Gastroenterol. 2023 Mar 14;29(10):1614-1626. doi: 10.3748/wjg.v29.i10.1614. World J Gastroenterol. 2023. PMID: 36970591 Free PMC article.

2

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.

Wang D, Yang X, Long J, Lin J, Mao J, Xie F, Wang Y, Wang Y, Xun Z, Bai Y, Yang X, Guan M, Pan J, Seery S, Sang X, Zhao H. Wang D, et al. Front Oncol. 2021 Apr 12;11:646979. doi: 10.3389/fonc.2021.646979. eCollection 2021. Front Oncol. 2021. PMID: 33912461 Free PMC article.

3

Comment on"Preoperative Single-dose Methylprednisolone Prevents Surgical Site Infections After Major Liver Resection: A Randomized Controlled Trial": Preoperative Single-dose Methylprednisolone Prevents Surgical Site Infections or Protects the Hepatic Function.

Zhang JW, Wang YY, Zhang L, Xu YY, Zhao HT, Lu X. Zhang JW, et al. Among authors: wang yy. Ann Surg. 2021 Dec 1;274(6):e906-e907. doi: 10.1097/SLA.0000000000004926. Ann Surg. 2021. PMID: 33938496 No abstract available.

4

Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy.

Yang X, Xu H, Zuo B, Yang X, Bian J, Long J, Wang D, Zhang J, Ning C, Wang Y, Xun Z, Wang Y, Lu X, Mao Y, Sang X, Zhao H. Yang X, et al. Hepatobiliary Surg Nutr. 2021 Aug;10(4):434-442. doi: 10.21037/hbsn-21-188. Hepatobiliary Surg Nutr. 2021. PMID: 34430522 Free PMC article.

5

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.

Mao J, Wang D, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, Li Y, Sun H, Xue J, Song Y, Zuo B, Zhang J, Bian J, Zhang T, Yang X, Zhang L, Sang X, Zhao H. Mao J, et al. J Immunother Cancer. 2021 Dec;9(12):e003334. doi: 10.1136/jitc-2021-003334. J Immunother Cancer. 2021. PMID: 34873013 Free PMC article.

6

A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer.

Zuo B, Yang X, Yang X, Bian J, Long J, Wang D, Ning C, Wang Y, Xun Z, Wang Y, Lu X, Mao Y, Sang X, Zhao H. Zuo B, et al. Cancer Immunol Immunother. 2022 Aug;71(8):1889-1896. doi: 10.1007/s00262-021-03121-0. Epub 2022 Jan 13. Cancer Immunol Immunother. 2022. PMID: 35022908 Free PMC article.

7

Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma.

Wang Y, Yang X, Wang D, Yang X, Wang Y, Long J, Zhou J, Lu Z, Mao Y, Sang X, Guan M, Zhao H. Wang Y, et al. Front Oncol. 2022 Mar 3;12:785535. doi: 10.3389/fonc.2022.785535. eCollection 2022. Front Oncol. 2022. PMID: 35311147 Free PMC article.

8

Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma.

Liao W, Long J, Li Y, Xie F, Xun Z, Wang Y, Yang X, Wang Y, Zhou K, Sang X, Zhao H. Liao W, et al. Front Cell Dev Biol. 2022 Jul 13;10:910749. doi: 10.3389/fcell.2022.910749. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35912098 Free PMC article.

9

Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: a multicenter retrospective study.

Zhang T, Yang X, Yang X, Zheng K, Wang Y, Wang Y, Sang X, Lu X, Xu Y, Wang X, Zhao H. Zhang T, et al. Am J Cancer Res. 2022 Jul 15;12(7):3455-3463. eCollection 2022. Am J Cancer Res. 2022. PMID: 35968352 Free PMC article.

10

Novel cellular therapies for hepatobiliary malignancies.

Xue JN, Wang YY, Wang YC, Zhang N, Zhang LH, Lu ZH, Zhao LJ, Zhao HT. Xue JN, et al. Among authors: wang yy, wang yc. Hepatobiliary Pancreat Dis Int. 2022 Oct;21(5):450-454. doi: 10.1016/j.hbpd.2022.08.014. Epub 2022 Sep 6. Hepatobiliary Pancreat Dis Int. 2022. PMID: 36100543 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,965 results

Search Page